Alpspitz Bioscience

Alpspitz Bioscience

Munich, Germany· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Alpspitz Bioscience is an early-stage diagnostics company targeting the massive global burden of cardiovascular diseases (CVDs). Its core innovation is the DefenceDX platform, a saliva test that uses AI to analyze inflammatory biomarkers, aiming to provide an easy-to-use, preventative screening tool for CVD risk. The company positions itself in the digital health and preventative diagnostics space, seeking partnerships to advance and commercialize its technology.

Cardiovascular

Technology Platform

DefenceDX: A saliva-based diagnostic platform combining AI for biomarker recognition, immunology to detect inflammation, and blockchain for data security. Aims to provide non-invasive screening for cardiovascular disease risk.

Opportunities

Targets the massive, growing market for preventative cardiovascular care with a non-invasive, user-friendly saliva test.
Leverages powerful trends in decentralized diagnostics, AI-driven personalized health, and a shift towards proactive wellness, which could appeal to consumers, employers, and healthcare providers.

Risk Factors

Faces high scientific risk in validating saliva biomarkers for CVD prediction and technical risk in developing robust AI algorithms.
The path to regulatory approval and market reimbursement is long, costly, and uncertain.
As a pre-revenue startup with no visible leadership team, it carries significant execution and funding risk.

Competitive Landscape

Competes with established blood-based lab tests for inflammatory markers (e.g., hs-CRP), advanced imaging for coronary calcium, and genetic risk scores. Also faces competition from a growing field of digital health startups developing AI-powered diagnostic and risk assessment tools, though a focused saliva-based CVD test may be a niche differentiator.